Drug structure-transport relationships

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 37, Issue 6, 2010, Pages 541-573

  Roberts, Michael S ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Malcolm Rowland; Physiological pharmacokinetics; Structure transport relationships

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; AMPHETAMINE; BARBITURIC ACID DERIVATIVE; CARTIA; CHLOROXYLENOL; CHROMIUM PHOSPHATE; DIAZEPAM; DICLOFENAC; ETHER; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; LIDOCAINE; METHAMPHETAMINE; MIDAZOLAM; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANIC NITRATE; PARACETAMOL; PENICILLIN G; PHENOL; PHENOL DERIVATIVE; PHENOTHIAZINE DERIVATIVE; UNCLASSIFIED DRUG; URETHAN;

AREA UNDER THE CURVE; ARTHUS PHENOMENON; BILE FLOW; BLOOD FLOW VELOCITY; BODY POSTURE; CELL TRANSPORT; CONFERENCE PAPER; CONTINUOUS INFUSION; DELAYED DRUG RELEASE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG DIFFUSION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SYNOVIAL FLUID LEVEL; DRUG TARGETING; DRUG TRANSPORT; HALF LIFE TIME; HEART FAILURE; HEART INFARCTION; HUMAN; HYDROGEN BOND; KIDNEY FAILURE; KIDNEY TUBULE EXCRETION; LIPOPHILICITY; LIVER CELL; LIVER CLEARANCE; MEMBRANE PERMEABILITY; NONHUMAN; ORGAN PERFUSION; PH MEASUREMENT; PHYSIOLOGICAL PROCESS; PLACENTA FUNCTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN METABOLISM; RECUMBENCY; SLEEP; STANDING; STEREOCHEMISTRY; STROKE; STRUCTURE ACTIVITY RELATION; SYSTEMIC CIRCULATION; TINNITUS; URINARY EXCRETION; URINE FLOW RATE; URINE PH; URINE VOLUME;

ABSORPTION; ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; LIVER; METABOLIC CLEARANCE RATE; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; TECHNOLOGY TRANSFER; TISSUE DISTRIBUTION;

EID: 79951773127     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-010-9174-0     Document Type: Conference Paper

References (183)

1. Beckett AH, Rowland M (1964) Rhythmic urinary excretion of amphetamine in man. Nature 204:1205-1206
2. Beckett AH, Rowland M (1965) Urinary excretion kinetics of methylamphetamine in man. Nature 206:1260-1261
3. Colantuoni A, Bertuglia S, Intaglietta M (1984) Effects of anesthesia on the spontaneous activity of the microvasculature. Int J Microcirc Clin Exp 3:13-28
4. Watt JA, Dickinson RG (1990) The effect of diethyl ether, pentobarbitone and urethane anaesthesia on diflunisal conjugation and disposition in rats. Xenobiotica 20:289-301 (Pubitemid 20145258)
5. Rowland M, Riegelman S (1967) Determination of acetylsalicylic acid and salicylic acid in plasma. J Pharm Sci 56:717-720
6. Roberts MS, Rumble RH, Wanwimolruk S, Thomas D, Brooks PM (1983) Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease. Eur J Clin Pharmacol 25:253-261 (Pubitemid 13000516)
7. Roberts MS, Cossum PA, Kilpatrick D (1985) Hepatic and extrahepatic metabolism of aspirinimplications for the selective inhibition of platelet cyclo-oxygenase by aspirin. N Engl J Med 313:1388-1389 (Pubitemid 15118306)
8. Roberts MS, Joyce RM, McLeod LJ, Vial JH, Seville PR (1986) Slow release aspirin and prostaglandin inhibition. Lancet 1:1153-1154 (Pubitemid 16109985)
9. Owen SG, Roberts MS, Friesen WT, Francis HW (1989) Salicylate pharmacokinetics in patients with rheumatoid arthritis. Br J Clin Pharmacol 28:449-461 (Pubitemid 19269784)
10. Rumble RH, Brooks PM, Roberts MS (1980) Metabolism of salicylate during chronic aspirin therapy. Br J Clin Pharmacol 9:41-45 (Pubitemid 10176894)
11. Furst DE, Tozer TN, Melmon KL (1979) Salicylate clearance, the resultant of protein-binding and metabolism. Clin Pharmacol Ther 26:380-389 (Pubitemid 10194679)
12. Shen J, Wanwimolruk S, Purves RD, McQueen EG, Roberts MS (1991) Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinaryexcretion rates following a single oral dose. J Pharmacokinet Biopharm 19:575-595
13. Aarons L, Hopkins K, Rowland M, Brossel S, Thiercelin JF (1989) Route of administration and sex- differences in the pharmacokinetics of aspirin, administered as its lysine salt. Pharm Res 6:660-666 (Pubitemid 19253876)
14. Aarons L, Clifton P, Fleming G, Rowland M (1980) Aspirin binding and the effect of albumin on spontaneous and enzyme-catalyzed hydrolysis. J Pharm Pharmacol 32:537-543 (Pubitemid 11237158)
15. McLeod LJ, Vonwitt RJ, Roberts MS (1986) Consequences of wasp stings. Med J Aust 144: 220-221
16. Aarons LJ, Bochner F, Rowland M (1977) A chronic dose-ranging kinetic study of salicylate in man. Br J Clin Pharmacol 61:456P-457P (Pubitemid 8209185)
17. Rowland M, Riegelman S, Harris PA, Sholkoff SD (1972) Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci 61:379-385
18. Sholkoff SD, Eyring EJ, Rowland M, Riegelma S (1967) Plasma and synovial fluid concentrations of acetylsalicylic acid in patients with rheumatoid arthritis. Arthritis Rheum 10:348-351
19. Roberts MS, Denton MJ (1980) Effect of posture and sleep on pharmacokinetics. I. Amoxycillin. Eur J Clin Pharmacol 18:175-183 (Pubitemid 10049070)
20. Rumble RH, Roberts MS, Scott AR (1988) The effects of posture on the pharmacokinetics of intramuscular benzylpenicillin. Eur J Clin Pharmacol 33:629-635 (Pubitemid 18063944)
21. Rumble RH, Roberts MS, Scott AR (1986) The effect of posture on the pharmacokinetics of intravenous benzyl penicillin. Eur J Clin Pharmacol 30:731-734 (Pubitemid 16018956)
22. Rumble RH, Roberts MS, Scott AR (1991) The effects of posture and sleep on the pharmacokinetics of paracetamol and its metabolites. Clin Pharmacokinet 20:167-173
23. Thomson PD, Melmon KL, Richardson JA, Cohn K, Steinbrunn W, Cudihee R, Rowland M (1973) Lidocaine pharmacokinetics in advanced heart failure. Ann Int Med 78:499-508
24. Thomson PD, Rowland M, Melmon KL (1971) The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man. Am Heart J 82:417-421
25. Patel IH, Soni PP, Fukuda EK, Smith DF, Leier CV, Boudoulas H (1990) The pharmacokinetics of midazolam in patients with congestive heart-failure. Br J Clin Pharmacol 29:565-569 (Pubitemid 20161306)
26. Rowland M, McLachlan A (1996) Pharmacokinetic considerations of regional administration and drug targeting: influence of site of input in target tissue and flux of binding protein. J Pharmacokinet Biopharm 24:369-387 (Pubitemid 27085407)
27. Levy RH, Rowland M (1974) Absorption kinetics of a series of local-anesthetics from rat subcutaneous tissue. I. J Pharmacokinet Biopharm 2:313-335
28. Roberts MS, Polack AE, Martin G, Blackburn HD (1979) The storage of selected substances in aqueous solution in polyethylene containers: the effect of some physicochemical factors on the disappearance kinetics of the substances. Int J Pharm 2:295-306 (Pubitemid 9161630)
29. Singh P, Roberts MS (1993) Dermal and underlying tissue pharmacokinetics of salicylic-acid after topical application. J Pharmacokinet Biopharm 21:337-373 (Pubitemid 24025265)
30. Lipschitz S, Campbell AJ, Roberts MS, Wanwimolruk S, McQueen EG, McQueen M, Firth LA (1991) Subcutaneous fluid administration in elderly subjects-validation of an under-used technique. J Am Geriatr Soc 39:6-9
31. Roberts MS, Lipschitz S, Campbell AJ, Wanwimolruk S, McQueen EG, McQueen M (1997) Modeling of subcutaneous absorption kinetics of infusion solutions in the elderly using technetium. J Pharmacokinet Biopharm 25:1-21 (Pubitemid 27475324)
32. Cross SE, Roberts MS (1993) Subcutaneous absorption kinetics and local tissue distribution of interferon and other solutes. J Pharm Pharmacol 45:606-609 (Pubitemid 23226749)
33. Charman WN, Stella VJ (1992) Lymphatic transport of drugs. CRC Press, Boca Raton
34. Porter CJH, Trevaskis NL, Charman WN (2007) Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6:231-248 (Pubitemid 46344627)
35. Owen SG, Francis HW, Roberts MS (1994) Disappearance kinetics of solutes from synovial fluid after intra-articular injection. Br J Clin Pharmacol 38:349-355 (Pubitemid 24314690)
36. Martin SW, Stevens AJ, Brennan BS, Reis ML, Gifford LA, Rowland M, Houston JB (1995) Regional drug delivery. 1. Permeability characteristics of the rat 6-day-old air pouch model of inflammation. Pharm Res 12:1980-1986 (Pubitemid 26031786)
37. Stevens AJ, Martin SW, Brennan BS, McLachlan A, Gifford LA, Rowland M, Houston B (1995) Regional drug delivery. 2. Relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation. Pharm Res 12:1987-1996 (Pubitemid 26031787)
38. Polack AE, Roberts MS, Schumann F (1970) Quantitative prediction of concentration changes due to permeation of solutes through polyethylene containers during autoclaving-a preliminary report. Am J Hosp Pharm 27:638-645
39. Roberts MS, Triggs EJ, Anderson RA (1975) Permeability of solutes through biological-membranes measured by a desorption technique. Nature 257:225-227
40. Roberts MS, Anderson RA, Swarbrick J (1977) Permeability of human epidermis to phenolic compounds. J Pharm Pharmacol 29:677-683 (Pubitemid 8200469)
41. Potts RO, Guy RH (1992) Predicting skin permeability. Pharm Res 9:663-669
42. Magnusson BM, Anissimov YG, Cross SE, Roberts MS (2004) Molecular size as the main determinant of solute maximum flux across skin. J Invest Dermatol 122:993-999 (Pubitemid 38581002)
43. Zhang Q, Grice JE, Li P, Jepps OG, Wang GJ, Roberts MS (2009) Skin solubility determines maximum transepidermal flux for similar size molecules. Pharm Res 26:1974-1985
44. Flynn GL, Yalkowsky SH, Roseman TJ (1974) Mass transport phenomena and models: theoretical concepts. J Pharm Sci 63:479-510
45. Penniston JT, Beckett L, Bentley DL, Hansch C (1969) Passive permeation of organic compounds through biological tissue: a non-steady-state theory. Mol Pharmacol 5:333-341
46. Suzuki A, Higuchi WI, Ho NF (1970) Theoretical model studies of drug absorption and transport in the gastrointestinal tract. J Pharm Sci 59:644-651
47. Flynn GL, Roberts MS (2011) Physical and chemical foundations for pharmacy practice. American Pharmacy Association, Washington
48. Roberts MS, Cross SE, Pellett MA (2002) Skin transport. In: Walters KA (ed) Dermatological and transdermal formulations. Marcel Dekker, New York, pp 89-195
49. Cleek RL, Bunge AL (1993) A new method for estimating dermal absorption from chemical exposure. 1. General approach. Pharm Res 10:497-506 (Pubitemid 23113039)
50. Scheuplein RJ, Blank IH (1971) Permeability of the skin. Physiol Rev 51:702-747
51. Cossum PA, Galbraith AJ, Roberts MS, Boyd GW (1978) Loss of nitroglycerin from intravenous infusion sets. Lancet II:349-350 (Pubitemid 9007376)
52. Cossum PA, Roberts MS (1981) Availability of isosorbide dinitrate, diazepam and chlormethiazole, from iv delivery systems. Eur J Clin Pharmacol 19:181-185 (Pubitemid 11188449)
53. Kowaluk EA, Roberts MS, Blackburn HD, Polack AE (1981) Interactions between drugs and polyvinyl chloride infusion bags. Am J Hosp Pharm 38:1308-1314 (Pubitemid 12245060)
54. Kowaluk EA, Roberts MS, Polack AE (1982) Interaction between drugs and intravenous delivery systems. Am J Hosp Pharm 39:460-467 (Pubitemid 12111690)
55. Kowaluk EA, Roberts MS, Polack AE (1985) A comparison of models describing the sorption of nitroglycerin and diazepam by plastic infusion systems: diffusion and compartment models. J Pharm Sci 74:625-633 (Pubitemid 15042123)
56. Kowaluk EA, Roberts MS, Polack AE (1986) Kinetics of sorption of ionisable solutes by plastic infusion bags. J Pharm Sci 75:562-570 (Pubitemid 16098038)
57. Rowland M (1984) Physiologic pharmacokinetic models: relevance, experience, and future trends. Drug Metab Rev 15:55-74 (Pubitemid 14123931)
58. Benowitz N, Forsyth RP, Melmon KL, Rowland M (1974) Lidocaine disposition kinetics in monkey and man. 2. Effects of hemorrhage and sympathomimetic drug administration. Clin Pharmacol Ther 16:99-109
59. Benowitz N, Forsyth RP, Melmon KL, Rowland M (1974) Lidocaine disposition kinetics in monkey and man. 1. Prediction by a perfusion model. Clin Pharmacol Ther 16:87-98
60. Cossum PA, Roberts MS (1985) Nitroglycerin disposition in human-blood. Eur J Clin Pharmacol 29:169-175
61. Rumble RH, Roberts MS, Wanwimolruk S (1981) Determination of aspirin and its major metabolites in plasma by high-performance liquid-chromatography without solvent-extraction. J Chromatogr 225:252-260 (Pubitemid 12198786)
62. Roberts MS, Cossum PA, Kilpatrick D (1985) Implications of hepatic and extrahepatic metabolism of aspirin in selective-inhibition of platelet cyclooxygenase. N Engl J Med 312:1388-1389 (Pubitemid 15118306)
63. Cossum PA, Roberts MS (1985) Metabolite inhibition of nitroglycerin metabolism in sheep tissue- homogenates. J Pharm Pharmacol 37:807-809 (Pubitemid 16236945)
64. Cossum PA, Roberts MS, Kilpatrick D, Yong AC (1986) Extrahepatic metabolism and distribution of aspirin in vascular beds of sheep. J Pharm Sci 75:731-737
65. Cossum PA, Roberts MS, Yong AC, Kilpatrick D (1986) Distribution and metabolism of nitro- glycerin and its metabolites in vascular beds of sheep. J Pharmacol Exp Ther 237:959-966 (Pubitemid 16088120)
66. Toon S, Rowland M (1983) Structure-pharmacokinetic relationships among the barbiturates in the rat. J Pharmacol Exp Ther 225:752-763 (Pubitemid 13070899)
67. Pang KS, Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well- stirred " model and a "parallel tube " model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653 (Pubitemid 8253670)
68. Pang KS, Rowland M (1977) Hepatic clearance of drugs. II. Experimental evidence for acceptance of the "well-stirred model over the "parallel tube model using lidocaine in the perfused rat liver in situ preparation. J Pharmacokinet Biopharm 5:655-680 (Pubitemid 8253671)
69. Pang KS, Rowland M (1977) Hepatic clearance of drugs. III. Additional experimental evidence supporting the "well-stirred " model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liver in situ preparation. J Pharmacokinet Biopharm 5:681-699 (Pubitemid 8253672)
70. Luxon BA, Forker EL (1982) Simulation and analysis of hepatic indicator dilution curves. Am J Physiol 243:G76-G89 (Pubitemid 12092536)
71. Koo AI, Liang IYS, Cheng AK (1975) The terminal hepatic micro-circulation in the rat. Q J Exp Physiol 60:261-266
72. Roberts MS, Rowland M (1985) Hepatic elimination-dispersion model. J Pharm Sci 74:585-587
73. Levenspiel O (1972) Chemical reaction engineering, 2nd edn. Wiley, New York
74. Wen CY, Fan LT (1975) Models for flow systems and chemical reactors. Dekker, New York
75. Langmuir I (1908) The velocity of reactions in gases moving through heated vessels and the effect of convection and diffusion. J Am Chem Soc 30:1742-1754
76. Dankwerts PV (1953) Continuous flow systems. Distribution of residence times. Chem Eng Sci 2:1-13
77. De Baas AF, Dop HV, Nieuwstadt FTM (1986) An application of the langevin equation for inhomogenous conditions to dispersion in a convective boundary layer. Q J R Meteorl Soc 112:165-180
78. Mei CC, Chian C (1994) Dispersion of small suspended particles in a wave boundary layer. J Phys Oceanogr 24:2479-2495
79. Snow VO, Clothier BE, Scotter DR, White RE (1994) Solute transport in a layered field soil: experiments and modelling using the convection-dispersion approach. J Contam Hydrol 16:339-358
80. Chinard FP, Enns T, Nolan MF (1962) Indicator-dilution studies with "diffusible indicators. Circ Res 10:473-490
81. Goresky CA (1963) A linear method for determining liver sinusoidal and extravascular volumes. Am J Physiol 204:626-640
82. Roberts MS, Rowland M (1986) A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J Pharmacokinet Biopharm 14:227-260 (Pubitemid 16028174)
83. Roberts MS, Rowland M (1986) A dispersion model of hepatic elimination: 2. Steady-state considerations-influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity. J Pharmacokinet Biopharm 14:261-288 (Pubitemid 16028175)
84. Roberts MS, Rowland M (1986) A dispersion model of hepatic elimination: 3. Application to metabolite formation and elimination kinetics. J Pharmacokinet Biopharm 14:289-308 (Pubitemid 16003714)
85. Roberts MS, Rowland M (1986) Correlation between in vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. J Pharm Pharmacol 38:177-181 (Pubitemid 16162503)
86. Chiba M, Ishii Y, Sugiyama Y (2009) Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J 11:262-276
87. Naritomi Y, Terashita S, Kagayama A, Sugiyama Y (2003) Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 31:580-588 (Pubitemid 36444167)
88. Ryan N, Byers JP, Fournier RL, Bachmann K (2003) Application of a convective-dispersion model to predict in vivo hepatic clearance from in vivo measurements utilizing cryopreserved human hepatocytes. Curr Drug Metab 4:357-369 (Pubitemid 37279361)
89. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M (2002) Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41:751-790 (Pubitemid 34948196)
90. Roberts MS, Donaldson JD, Jackett D (1989) Availability predictions by hepatic elimination models for Michaelis-Menten kinetics. J Pharmacokinet Biopharm 17:687-719 (Pubitemid 20162870)
91. Hisaka A, Sugiyama Y (2000) Problems of mixed boundary conditions for convection-dispersion models in the analysis of local pharmacokinetics. J Pharm Sci 89:1587-1588
92. Roberts MS, Anissimov YG, Weiss M (2000) Commentary: using the convection-dispersion model and transit time density functions in the analysis of organ distribution kinetics. J Pharm Sci 89:1579-1586
93. Sahin S, Oliver RE, Rowland M (2005) Effect of boundary conditions on the parameters estimated from axial dispersion model. FABD J Pharm Sci 30:7-16
94. Weiss M, Stedtler C, Roberts MS (1997) On the validity of the dispersion model of hepatic drug elimination when intravascular transit time densities are long-tailed. Bull Math Biol 59:911-929 (Pubitemid 28378119)
95. Weiss M, Roberts MS (1996) Tissue distribution kinetics as a determinant of transit time dispersion of drugs in organs: application of a stochastic model for the rat hindlimb. J Pharmacokinet Biopharm 24:173-196 (Pubitemid 26300484)
96. Anissimov YG, Roberts MS (2002) A compartmental model of hepatic disposition kinetics. 1. Model development and application to linear kinetics. J Pharmacokinet Pharmacodyn 29:131-156
97. Weiss M, Li P, Roberts MS (2010) An improved nonlinear model describing the hepatic pharmacokinetics of digoxin: evidence for two functionally different uptake systems and saturable binding. Pharm Res 27:1999-2007
98. Chou CH, Evans AM, Fornasini G, Rowland M (1993) Relationship between lipophilicity and hepatic dispersion and distribution for a homologous series of barbiturates in the isolated-perfused in situ rat-liver. Drug Metab Dispos 21:933-938 (Pubitemid 23298462)
99. Chou CH, McLachlan AJ, Rowland M (1995) Membrane-permeability and lipophilicity in the isolated-perfused rat-liver-5-ethyl barbituric-acid and other compounds. J Pharmacol Exp Ther 275:933-940 (Pubitemid 26027052)
100. Hussein Z, McLachlan AJ, Rowland M (1994) Distribution kinetics of salicylic-acid in the isolated- perfused rat-liver assessed using moment analysis and the 2-compartment axial-dispersion model. Pharm Res 11:1337-1345 (Pubitemid 24287416)
101. Evans AM, Hussein Z, Rowland M (1991) A 2-compartment dispersion model describes the hepatic outflow profile of diclofenac in the presence of its binding-protein. J Pharm Pharmacol 43:709-714
102. Evans AM, Hussein Z, Rowland M (1993) Influence of albumin on the distribution and elimination kinetics of diclofenac in the isolated perfused-rat-liver-analysis by the impulse-response technique and the dispersion model. J Pharm Sci 82:421-428 (Pubitemid 23150439)
103. Chou CH, Rowland M (1997) Effect of altered tissue binding on the disposition of barbital in the isolated perfused rat liver: application of the axial dispersion model. J Pharm Sci 86:1310-1314 (Pubitemid 27486107)
104. Sahin S, Rowland M (2007) Application of the dispersion model to describe disposition kinetics of markers in the dual perfused rat liver. Drug Metab Dispos 35:1119-1125 (Pubitemid 46956432)
105. Sahin S, Rowland M (2007) Influence of erythrocytes on the hepatic distribution kinetics of urea and thiourea. Eur J Pharm Sci 31:180-189 (Pubitemid 46818979)
106. Fanning KJ, Anissimov YG, Roberts MS (2009) Sulphonylurea physicochemical-pharmacokinetic relationships in the pancreas and liver. J Pharm Sci 98:2807-2821
107. Hung DY, Mellick GD, Whitehead BD, Roberts MS (1998) The effect of protein binding on the hepatic first pass of O-acyl salicylate derivatives in the rat. J Pharm Pharmacol 50:63-69 (Pubitemid 28052522)
108. Roberts MS, Ballinger LN, Weiss M (1998) Relative dispersions of intra-albumin transit times across rat and elasmobranch perfused livers, and implications for intra- and inter-species scaling of hepatic clearance using microsomal data. J Pharm Pharmacol 50:865-870 (Pubitemid 28421153)
109. Weiss M, Ballinger LN, Roberts MS (1998) Kinetic analysis of vascular marker distribution in perfused rat livers after regeneration following partial hepatectomy. J Hepatol 29:476-481 (Pubitemid 28396667)
110. Hung DY, Mellick GD, Anissimov YG, Weiss M, Roberts MS (1998) Hepatic disposition and metabolite kinetics of a homologous series of diflunisal esters. J Pharm Sci 87:943-951 (Pubitemid 28381251)
111. Hung DY, Mellick GD, Anissimov YG, Weiss M, Roberts MS (1998) Hepatic structure-pharma- cokinetic relationships: the hepatic disposition and metabolite kinetics of a homologous series of O-acyl derivatives of salicylic acid. Br J Pharmacol 124:1475-1483 (Pubitemid 28360572)
112. Hung DY, Burczynski FJ, Chang P, Lewis A, Masci PP, Siebert GA, Anissimov YG, Roberts MS (2003) Fatty acid binding protein is a major determinant of hepatic pharmacokinetics of palmitate and its metabolites. Am J Physiol Gastrointest Liver Physiol 284:G423-G433 (Pubitemid 36227890)
113. Hung DY, Chang P, Cheung K, McWhinney B, Masci PP, Weiss M, Roberts MS (2002) Cationic drug pharmacokinetics in diseased livers determined by fibrosis index, hepatic protein content, microsomal activity, and nature of drug. J Pharmacol Exp Ther 301:1079-1087 (Pubitemid 34595100)
114. Hung DY, Chang P, Weiss M, Roberts MS (2001) Structure-hepatic disposition relationships for cationic drugs in isolated perfused rat livers: transmembrane exchange and cytoplasmic binding process. J Pharmacol Exp Ther 297:780-789 (Pubitemid 32378012)
115. Hung DY, Siebert GA, Chang P, Anissimov YG, Roberts MS (2004) Disposition kinetics of propranolol isomers in the perfused rat liver. J Pharmacol Exp Ther 311:822-829 (Pubitemid 39391572)
116. Hung DY, Siebert GA, Chang P, Whitehouse MW, Fletcher L, Crawford DHG, Roberts MS (2006) Hepatic pharmacokinetics of propranolol in rats with adjuvant-induced systemic inflammation. Am J Physiol Gastrointest Liver Physiol 290:G343-G351
117. Siebert GA, Hung DY, Chang P, Roberts MS (2004) Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs. J Pharmacol Exp Ther 308: 228-235 (Pubitemid 38090722)
118. Weiss M, Hung DY, Poenicke K, Roberts MS (2008) Kinetic analysis of saturable hepatic uptake of digoxin and its inhibition by rifampicin. Eur J Pharm Sci 34:345-350
119. Park S, Ropella GEP, Kim SHJ, Roberts MS, Hunt CA (2009) Computational strategies unravel and trace how liver disease changes hepatic drug disposition. J Pharmacol Exp Ther 328:294-305
120. Yan L, Ropella GE, Kim SH, Roberts MS, Hunt CA (2008) Modelling and simulation of hepatic drug disposition using a physiologically based, multi-agent in silico liver. Pharm Res 25:1023-1036
121. Park S, Kim SH, Ropella GE, Roberts MS, Hunt CA (2010) Tracing multiscale mechanisms of drug disposition in normal and diseased livers. J Pharmacol Exp Ther 334:124-136
122. McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ (2004) Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 32:1247-1253 (Pubitemid 39410908)
123. Lave T, Chapman K, Goldsmith P, Rowland M (2009) Human clearance prediction: shifting the paradigm. Expert Opin Drug Metab Toxicol 5:1039-1048
124. Riegelman S, Loo JC, Rowland M (1968) Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. J Pharm Sci 57:117-123
125. Bischoff KB, Dedrick RL (1968) Thiopental pharmacokinetics. J Pharm Sci 57:1346-1351
126. Perl W, Chinard FP (1968) A convection-diffusion model of indicator transport through an organ. Circ Res 22:273-298
127. Mayer JM, Hall SD, Rowland M (1988) Relationship between lipophilicity and tubular reabsorption for a series of 5-alkyl-5-ethylbarbituric acids in the isolated perfused rat-kidney preparation. J Pharm Sci 77:359-364
128. Hall S, Rowland M (1984) Relationship between renal clearance, protein binding and urine flow for digitoxin, a compound of low clearance in the isolated perfused rat kidney. J Pharmacol Exp Ther 228:174-179 (Pubitemid 14223398)
129. Hall S, Rowland M (1985) Influence of fraction unbound upon the renal clearance of furosemide in the isolated perfused rat kidney. J Pharmacol Exp Ther 232:263-268 (Pubitemid 15193684)
130. Wu ZY, Rivory LP, Roberts MS (1993) Physiological pharmacokinetics of solutes in perfused rat hindlimb: characterisation of the physiology with changing perfusate flow, protein content and temperature using statistical moment analysis. J Pharmacokinet Biopharm 21:653-688 (Pubitemid 24052758)
131. Weiss M, Koester A, Wu ZY, Roberts MS (1997) Distribution kinetics of diazepam, lidocaine and antipyrine in the isolated perfused rat hindlimb. Pharm Res 14:1640-1643 (Pubitemid 28009219)
132. Roberts MS, Wu ZY, Rivory LP, Smithers BM, Egerton WS, Weiss M (1997) Relative dispersion of intravascular transit times during isolated human limb perfusions for recurrent melanoma. Br J Clin Pharmacol 44:347-351 (Pubitemid 27402109)
133. Wu ZY, Smithers BM, Parsons PG, Roberts MS (1997) The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft. Br J Cancer 75:1160-1166 (Pubitemid 27140028)
134. Thompson JF, Siebert GA, Anissimov YG, Smithers BM, Doubrovsky A, Anderson CD, Roberts MS (2001) Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer 85:157-165 (Pubitemid 32700296)
135. Wu ZY, Smithers BM, Anderson C, Roberts MS (2000) Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment? Melanoma Res 10:47-54 (Pubitemid 30127829)
136. Roberts MS, Cross SE (1999) A physiological pharmacokinetic model for solute disposition in tissues below a topical application site. Pharm Res 16:1392-1398 (Pubitemid 29449376)
137. Roberts MS, Wu ZY, Weiss M (2000) Kinetics of propranolol uptake in muscle, skin, and fat of the isolated perfused rat hindlimb. Eur J Pharm Sci 11:165-172 (Pubitemid 30479858)
138. Heatherington AC, Rowland M (1995) Discrepancies in pharmacokinetic parameter estimation between bolus and infusion studies in the perfused rat hindlimb. J Pharmacokinet Biopharm 23:441-462 (Pubitemid 26116531)
139. Oliver RE, Heatherington AC, Jones AF, Rowland M (1997) A physiologically based pharmaco- kinetic model incorporating dispersion principles to describe solute distribution in the perfused rat hindlimb preparation. J Pharmacokinet Biopharm 25:389-412 (Pubitemid 28186444)
140. Bernus I, Roberts MS, Rasiah RL, Mortimer RH (1999) Statistical moments for placental transfer of solutes in man. J Pharm Pharmacol 51:1381-1389 (Pubitemid 30064067)
141. Foster KA, Mellick GD, Weiss M, Roberts MS (2000) An isolated in situ rat head perfusion model for pharmacokinetic studies. Pharm Res 17:127-134 (Pubitemid 30158359)
142. Foster KA, Weiss M, Roberts MS (2002) Distribution kinetics of solutes in the isolated in situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. J Pharm Pharmacol 54:373-382 (Pubitemid 34232337)
143. Fanning KJ, Roberts MS (2007) Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. Pharm Res 24:512-520 (Pubitemid 46295154)
144. Liu X, Wang JY, Khlentzos AM, Fontaine F, Nikolovski J, Goh LA, Roberts MS (2009) Influence of perfusate composition on drug disposition in the in situ perfused rat lung. Int J Pharm 382:192-197
145. Oliver RE, Jones AF, Rowland M (2001) A whole-body physiologically based pharmacokinetic model incorporating dispersion concepts: short and long time characteristics. J Pharmacokinet Pharmacodyn 28:27-55
146. Weiss M (1983) Hemodynamic influences upon the variance of disposition residence time distribution of drugs. J Pharmacokinet Biopharm 11:63-75 (Pubitemid 13055142)
147. Weiss M (2009) Cardiac output and systemic transit time dispersion as determinants of circulatory mixing time: a simulation study. J App Physiol 107:445-449
148. Blakey GE, Nestorov IA, Arundel PA, Aarons LJ, Rowland M (1997) Quantitative structure- pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat. J Pharmacokinet Biopharm 25:277-312 (Pubitemid 28045711)
149. Nestorov I, Aarons L, Rowland M (1998) Quantitative structure- pharmacokinetics relationships: II. A mechanistically based model to evaluate the relationship between tissue distribution parameters and compound lipophilicity. J Pharmacokinet Biopharm 26:521-545 (Pubitemid 29157781)
150. Ballard P, Arundel PA, Leahy DE, Rowland M (2003) Prediction of in vivo tissue distribution from in vitro data. 2. Influence of albumin diffusion from tissue pieces during an in vitro incubation on estimated tissue-to-unbound plasma partition coefficients (kpu). Pharm Res 20:857-863 (Pubitemid 36628430)
151. Ballard P, Leahy DE, Rowland M (2003) Prediction of in vivo tissue distribution from in vitro data. 3. Correlation between in vitro and in vivo tissue distribution of a homologous series of nine 5-n- alkyl-5-ethyl barbituric acids. Pharm Res 20:864-872 (Pubitemid 36628431)
152. Gueorguieva I, Nestorov IA, Murby S, Gisbert S, Collins B, Dickens K, Duffy J, Hussain Z, Rowland M (2004) Development of a whole body physiologically based model to characterise the pharmacokinetics of benzodiazepines. 1: estimation of rat tissue-plasma partition ratios. J Pharmacokinet Pharmacodyn 31:269-298 (Pubitemid 39287337)
153. Rodgers T, Leahy D, Rowland M (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259-1276 (Pubitemid 40904190)
154. Rodgers T, Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257 (Pubitemid 43874439)
155. Rodgers T, Rowland M (2007) Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 24:918-933 (Pubitemid 46675393)
156. Roberts MS, Roberts MJ, Robertson TA, Sanchez W, Thorling C, Zou YH, Zhao X, Becker W, Zvyagin AV (2008) In vitro and in vivo imaging of xenobiotic transport in human skin and in the rat liver. J Biophotonics 1:478-493
157. Hunt CA, Ropella GEP, Yan L, Hung DY, Roberts MS (2006) Physiologically based synthetic models of hepatic disposition. J Pharmacokinet Pharmacodyn 33:737-772 (Pubitemid 44819260)
158. Simcyp Ltd. The Simcyp simulator. http://www.simcyp.com/ProductServices/ Simulator/
159. Sheiner LB, Rosenburg B, Melmon KL (1972) Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 5:441-459
160. Dollery CT (2006) Clinical pharmacology-the first 75 years and a view of the future. Br J Clin Pharmacol 61:650-665 (Pubitemid 43794790)
161. Rowland M, Benet LZ, Graham GG (1973) Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1:123-136
162. Aarons L, Rowland M, Khan A, Taborelli G, Ferrea G, Tarantino V, Fioredda F, Rosina-Parenti R, Cavenaghi L, Borgonovi M (1998) Plasma and tonsillar tissue pharmacokinetics of teicoplanin following intramuscular administration to children. Eur J Pharm Sci 6:265-270 (Pubitemid 28468533)
163. Chan E, McLachlan AJ, Pegg M, MacKay AD, Cole RB, Rowland M (1994)
164. Roberts DM, Southcott E, Potter JM, Roberts MS, Eddleston M, Buckley NA (2006) Pharmaco-kinetics of digoxin cross-reacting substances in patients with acute yellow oleander (Thevetia peruviona) poisoning including the effect of activated charcoal. Ther Drug Monit 28:784-792 (Pubitemid 44967659)
165. Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C (2010) Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci 40:125-131
166. Lesko LJ, Rowland M, Peck CC, Blaschke TF (2000) Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res 17:1335-1344 (Pubitemid 32109484)
167. Vozeh S, Steimer JL, Rowland M, Morselli P, Mentre F, Balant LP, Aarons L (1996) The use of population pharmacokinetics in drug development. Clin Pharmacokinet 30:81-93 (Pubitemid 26069034)
168. Rowland M, Tozer TN (1995) Clinical pharmacokinetics concepts and applications, 3rd edn. Williams & Wilkins, Baltimore
169. Roberts MS (1973) Percutaneous absorption of phenol. MSc Thesis, University of Sydney, Sydney
170. Singh P, Roberts MS (1994) Effects of vasoconstriction on dermal pharmacokinetics and local tissue distribution of compounds. J Pharm Sci 83:783-791 (Pubitemid 24233750)
171. Li P, Wang GJ, Robertson TA, Roberts MS (2009) Liver transporters in hepatic drug disposition: an update. Current Drug Metabolism 10:482-498
172. Brauer RW, Leong GF, McElroy RF, Holloway RJ (1956) Circulatory pathways in the rat liver as revealed by p32 chromic phosphate colloid uptake in the isolated perfused liver preparation. Am J Physiol 184:593-598
173. Rowland M, Leitch D, Fleming G, Smith B (1984) Protein binding and hepatic clearance: discrimination between models of hepatic clearance with diazepam, a drug of high intrinsic clearance, in the isolated perfused rat liver preparation. J Pharmacokinet Biopharm 12:129-147 (Pubitemid 14009858)
174. Weiss M (1999) Cellular pharmacokinetics: effects of cytoplasmic diffusion and binding on organ transit time distribution. J Pharmacokinet Biopharm 27:233-256 (Pubitemid 30136511)
175. Weiss M (1999) Pharmacokinetics in organs and the intact body: model validation and reduction. Eur J Pharm Sci 7:119-127 (Pubitemid 29056234)
176. Huang SM, Goodsaid F, Rahman A, Frueh F, Lesko LJ (2006) Application of pharmacogenomics in clinical pharmacology. Toxicol Mech Methods 16:89-99
177. Rowland M (2006) Microdosing and the 3Rs. NC3Rs Feb#5:1-7. http://www.nc3rs.org.uk/ downloaddoc.asp?id=339&page=193&skin=330. Accessed 21 Oct 2010
178. Rowland M (2009) Physiological pharmacokinetics: coming of age. In: American Society of Clinical Pharmacology and Therapeutics (ASCPT) annual meeting, Friday March 20, 2009. http://www.ascpt.org/Portals/8/docs/Meetings/ 2009%20Annual%20Meeting/Friday/Featured%20Speaker%20-%20Malcolm%20Rowland.pdf. Accessed 21 Oct 2010
179. Rowland M, Peck C, Tucker G (2011) Physiologically based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51:45-73
180. http://german.about.com/library/blgermyth12.htm. Accessed Feb 2010
181. Zondek B (1942) The excretion of halogenated phenols and their use in the treatment of urogenital infections. J Urol 48:747-758
182. Roberts MS, Cossum PA, Galbraith AJ, Boyd GW (1980) The availability of nitroglycerin from parenteral solutions. J Pharm Pharmacol 32:237-244 (Pubitemid 10075454)
183. Roberts MS, Donaldson JD, Rowland M (1988) Models of hepatic elimination; comparison of stochastic models to describe residence time distributions and to predict the influence of drug distribution, enzyme heterogeneity and systemic recycling on hepatic elimination. J Pharmacokinet Biopharm 16:41-84